Last reviewed · How we verify

Ketofol 1:3 ratio

Kasr El Aini Hospital · FDA-approved active Small molecule

Ketofol is a fixed-ratio combination of ketamine and propofol that produces rapid sedation and anesthesia through dual action on NMDA receptors and GABA-A receptors.

Ketofol is a fixed-ratio combination of ketamine and propofol that produces rapid sedation and anesthesia through dual action on NMDA receptors and GABA-A receptors. Used for Induction and maintenance of general anesthesia, Sedation in intensive care settings.

At a glance

Generic nameKetofol 1:3 ratio
SponsorKasr El Aini Hospital
Drug classAnesthetic combination
TargetNMDA receptor (ketamine); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ketamine acts as an NMDA receptor antagonist providing dissociative anesthesia and analgesia, while propofol is a GABA-A receptor agonist that enhances inhibitory neurotransmission. The 1:3 ratio combines ketamine's analgesic and dissociative properties with propofol's rapid onset and smooth sedation profile, potentially reducing the adverse effects of each agent when used alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: